Journal

Clinical AI disclaimers matter, but their effect depends on the claim, law, product design and actual use; they are not an automatic shield against liability.

Before mandatory clinical AI use, staff need clear scope, training, review time, escalation and indemnity arrangements, not a vague instruction to approve outputs.

A proposed NHS stop-use framework connects AI safety signals with proportionate restrictions, continuity of care, investigation and explicit reinstatement criteria.

Administrative AI can influence access, referrals and follow-up without diagnosing illness: follow a fictional patient journey and identify practical safeguards.

A practical governance approach for small GP practices distinguishes reusable supplier assurance from the local decisions needed for safe AI deployment.

A task-based approach to shadow AI in NHS services separates general learning from patient-data processing and makes approved alternatives easier to use.

AI licences and logins do not establish patient benefit: a proposed NHS dashboard measures outcomes, correction work, access and sustained value.

A clinical AI supplier's safety case is only part of NHS assurance: local workflows, integrations, ownership and fallback arrangements need their own assessment.

How engagement, subscriptions, growth and advertising can shape healthcare AI, and what transparent businesses should disclose and measure.

How incremental feature changes can outgrow an AI scribe's original approval, and what NHS teams should reassess before drafting becomes action.

Why model benchmark scores do not automatically translate into better clinician performance, and how to evaluate the actual human-AI workflow.

Why AI suggestions must remain separate from records of advice and consent that actually occurred, with practical review and correction examples.